Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study

por Lindholm, C., Olofsson, E., Creignou, M., Nilsson, L., Garelius, H. Gravdahl, Cammenga, J., Ljungman, P., Ejerblad, E., Tobiasson, M.
Publicado 2022

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden

por Juliusson, G, Abrahamsson, J, Lazarevic, V, Antunovic, P, Derolf, Å, Garelius, H, Lehmann, S, Myhr-Eriksson, K, Möllgård, L, Uggla, B, Wahlin, A, Wennström, L, Höglund, M
Publicado 2017

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

por Tobiasson, M, Dybedahl, I, Holm, M S, Karimi, M, Brandefors, L, Garelius, H, Grövdal, M, Högh-Dufva, I, Grønbæk, K, Jansson, M, Marcher, C, Nilsson, L, Kittang, A O, Porwit, A, Saft, L, Möllgård, L, Hellström-Lindberg, E
Publicado 2014

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome

por Garelius, H. K. G., Johnston, W. T., Smith, A. G., Park, S., de Swart, L., Fenaux, P., Symeonidis, A., Sanz, G., Čermák, J., Stauder, R., Malcovati, L., Mittelman, M., van de Loosdrecht, A. A., van Marrewijk, C. J., Bowen, D., Crouch, S., de Witte, T. J. M., Hellström‐Lindberg, E.
Publicado 2016